Clinical Trial Update: Tolerance and Pharmacokinetics of TQB2450 [Phase 1]

View source ↗

Summary

Phase 1 study update reporting tolerability and pharmacokinetics of TQB2450 in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Tumor | Phase 1 | Status: UNKNOWN